arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

MADRIGAL PHARMACEUTICALS, INC.

MDGL
$400.54 ▼ -0.25 (-0.06%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
69 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

MADRIGAL PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $11.7B
Dividend Yield —
Revenue Growth 50.1% ↘
Op. Margin 13.0% ↗
ROIC 4.6% ↗
FCF / Share $3.99 ↗
Trailing P/E 210.8x
Price / Book 14.8x
FCF Yield 1.0%
Debt / Equity 0.54
info Valuation on last close. End-of-day price, Nov 5, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$431.27M
↑ +50.1% —
Net Income Profit after all expenses
$-94.39M
↓ -28.9% —
Operating Margin Operating profit as % of sales
13.0%
↑ +184.0% 8th
FCF / Share Free cash flow per share
$3.99
↑ +509.2% —
Long-Term Debt Long-term obligations
$341.27M
— +0.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
8
Returns ↑
17
Financial Health
47
Cash Quality ↓
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 69 quarters